We came across a bullish thesis on Abbott Laboratories on r/ValueInvesting subreddit by anonymous_sheep1. In this article, we ...

Abbott (ABT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Abbott Laboratories CEO Robert Ford unpacked his company’s latest quarterly report in a Thursday interview with CNBC’s Jim ...

Wells Fargo, Abbott, and American Express lead Zacks highlights, while TSS surges on AI growth and MLP eyes land monetization ...

Today, in an otherwise positive market, I was discouraged to get a mixed update from Abbott Labs, medical technology company ...

Every investor in Abbott Laboratories (NYSE:ABT) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 80% ownership. In ...

Abbott Laboratories (NYSE:ABT) stock drops as the company reported mixed Q2 2025 results and sets its Q3 guidance below ...

Abbott Laboratories shares slumped Thursday after the drugmaker narrowed its full-year outlook, even as it posted better-than ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott Laboratories is a mammoth healthcare business whose market cap is around $180 billion. Even at a $30,000 investment, you would need the stock to be worth more than 33 times its valuation ...

Abbott Laboratories' long-term plan is to make headway in this massive market by launching products adapted to different regions. Abbott isn't just a diabetes company, though.

Abbott Laboratories closed 6.52% below its 52-week high of $141.23, which the company reached on March 4th.